NeuroSense Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Income	-9.8	-10.11	-10.49	-3.22	-2.83	-1.22
Depreciation & Amortization	0.02	0.02	0.01	0	0	-
Loss (Gain) From Sale of Assets	-	-	-	0.01	-	-
Stock-Based Compensation	0.82	1.54	1.73	1.22	2.06	0.61
Other Operating Activities	-1.81	-1.72	0.04	0.18	-0	-
Change in Accounts Receivable	0.04	-	-	-	-0.01	-0
Change in Accounts Payable	0.39	0.96	0.46	-0.02	0.03	0.02
Change in Other Net Operating Assets	0.14	0.95	0.64	0.29	0.05	0.01
Operating Cash Flow	-10.2	-8.35	-7.62	-1.54	-0.7	-0.58
Capital Expenditures	-0.01	-0.03	-0.07	-0.02	-0.01	-0.01
Investment in Securities	-	3.5	-3.5	-	-	-
Other Investing Activities	0	-0	-0.02	-	-	-0.02
Investing Cash Flow	-0	3.47	-3.59	-0.02	-0.01	-0.03
Short-Term Debt Repaid	-	-	-	-	-	-0
Total Debt Repaid	-	-	-	-	-	-0
Net Debt Issued (Repaid)	-	-	-	-	-	-0
Issuance of Common Stock	4.32	3.98	3.87	11.9	0.51	1.42
Other Financing Activities	-	-	-0.1	-	-	-
Financing Cash Flow	4.32	3.98	3.77	11.9	0.51	1.42
Foreign Exchange Rate Adjustments	0.01	0.01	-0.09	0.02	-	-
Net Cash Flow	-5.88	-0.9	-7.52	10.36	-0.2	0.81
Free Cash Flow	-10.21	-8.38	-7.69	-1.56	-0.7	-0.59
Free Cash Flow Per Share	-0.63	-0.61	-0.67	-0.25	-0.13	-0.13
Levered Free Cash Flow	-6.63	-4.26	-3.8	-0.47	0.28	-
Unlevered Free Cash Flow	-6.61	-4.26	-3.8	-0.47	0.28	-
Change in Net Working Capital	-0.56	-1.74	-1.12	-0.2	-0.03	-

Source: S&P Capital IQ. Standard template. Financial Sources.